Endothelial Dysfunction as a Predictive Marker of Acute Graft-Versus-Host Disease in Adult Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

N/ACompletedNCT07508345

Fondazione IRCCS Policlinico San Matteo di Pavia50 enrolled

Overview

Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Study Type

OBSERVATIONAL

Enrollment

Conditions

GVHD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged between 18 and 70 years old * First allogeneic hematopoietic stem cell (HSC) transplant for hematological disease * Use of HSCs from bone marrow, peripheral blood, or cord blood * Use of HLA-identical related donors, haploidentical related donors, HLA-identical registry donors, registry donors with mismatches at major HLA loci * Signing of informed consent Exclusion Criteria: * Age \< 18 years or \>70 years * Patients receiving allogeneic HSC transplantation for non-hematologic disease * Second or subsequent allogeneic HSC transplantation

Locations (1)

Fondazione IRCCS Policlinico San Matteo di Pavia

Pavia, Pavia, Italy

Outcomes

Primary Outcomes

Predict the risk of aGvHD onset.

Assess whether the CEC count in peripheral blood, analyzed at baseline T0, can predict the risk of acute GvHD onset.

Time frame: During the 18-month enrollment period, approximately 50 adult patients receiving HSCT are expected to be enrolled.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.